<DOC>
	<DOC>NCT00363116</DOC>
	<brief_summary>The purpose of the study is to determine the safety and efficacy of two dosing regimens of daclizumab in simultaneous kidney/pancreas transplant recipients.</brief_summary>
	<brief_title>A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , &amp; Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients</brief_title>
	<detailed_description>The purpose of the study is to determine the safety and efficacy of two dosing regimens of daclizumab as an adjunctive immunosuppressive agent in simultaneous kidney/pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and steroids as primary maintenance immunosuppression.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Simultaneous kidney/pancreas transplant recipients Insulin dependent Type 1 or 2 diabetes pretransplant Recipient age 1865 years Donor age 565 years Women must have negative serum pregnancy test and practice birth control for study duration Negative Tcell crossmatch Parent (or guardian) is able to understand the consent form and give written informed consent Prior treatment with daclizumab Known sensitivity or contraindication to tacrolimus, MMF, or steroids Patient with significant or active infection Patients with a positive lymphocytotoxic crossmatch using donor lymphocytes and recipient serum Patients whose life expectancy is severely limited by diseases other than renal disease Ongoing substance abuse, drug or alcohol Major ongoing psychiatric illness or recent history of noncompliance Insufficient cardiovascular reserve Malignancy within last 5 years, excluding nonmelanoma skin cancers Serologic evidence of infection with HIV or Hepatitis B surface antigen positive Investigational drug within 30 days prior to transplant surgery AntiT cell therapy within 30 days prior to transplant surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Kidney transplant</keyword>
	<keyword>Pancreas transplant</keyword>
	<keyword>Daclizumab</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Steroids</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Acute allograft rejection</keyword>
</DOC>